Nuwellis Inc. Prices $6 Million Public Offering of Common Stock
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2026
0mins
Source: Newsfilter
Nuwellis Inc. is experiencing a significant pre-market decline of 12.08%, hitting a 52-week low.
The company announced a public offering of 20 million shares at $0.30 per share, expected to raise approximately $6 million to support medical technology solutions for patients with cardiorenal conditions. This offering includes Series C and D Warrants, which will be exercisable for five years following stockholder approval, indicating a strategic move to enhance financial flexibility. Additionally, Nuwellis engaged in private placement transactions to reduce the exercise price of previously issued warrants, further improving its capital structure.
This public offering reflects Nuwellis's commitment to accessing capital markets effectively, although the current price drop may raise concerns among investors regarding the company's market position and future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NUWE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NUWE
Wall Street analysts forecast NUWE stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 3.290
Low
5.50
Averages
5.50
High
5.50
Current: 3.290
Low
5.50
Averages
5.50
High
5.50
No data
About NUWE
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nuwellis Celebrates Five-Year Support for PC4 Conference
- Support for Pediatric Care: Nuwellis has consistently supported the Pediatric Cardiac Critical Care Consortium (PC4) annual conference over the past five years, aiming to enhance the quality of care for critically ill children with cardiovascular diseases, reflecting the company's strong commitment to improving pediatric care.
- Education and Exchange: By collaborating with leading pediatric cardiac critical care institutions, Nuwellis has fostered clinician education and scientific exchange on fluid management strategies, helping to raise awareness of the importance of fluid balance and improving care outcomes for critically ill patients.
- Device Utilization Promotion: Many top pediatric cardiac centers participating in PC4 utilize the Aquadex® SmartFlow® system to manage fluid overload in complex pediatric patients, with Nuwellis supporting multidisciplinary care teams through ongoing education and training to ensure effective device use and patient safety.
- Market Strategic Focus: Nuwellis views the pediatric market as a critical strategic focus, continuing to strengthen relationships with leading pediatric centers and physician leaders while supporting forums and collaborative initiatives to facilitate the exchange of best practices in fluid management.
See More
Nuwellis CEO Outlines Strategic Priorities for 2026
- Leadership Transition: Nuwellis announced that Mike McCormick will assume the role of CEO on June 30, 2026, while former CEO John Erb will remain as Chairman, aiming to leverage the company's growing commercial momentum and improved margins.
- Strong Financial Performance: In Q1 2026, Nuwellis achieved a 26% year-over-year revenue growth with a gross margin of 70.1%, a 14-point improvement from the previous year, reflecting the continued adoption of its technology and employee dedication.
- Strategic Acquisition: Nuwellis acquired Rendiatech, Inc., enhancing its market position in the ICU by adding automated kidney function monitoring technology to its portfolio, creating additional growth opportunities within its existing customer base.
- Optimized Capital Management: The company strengthened its capital position to execute key commercial and development initiatives while maintaining its Nasdaq listing, focusing on disciplined capital allocation to drive long-term shareholder value.
See More
Nuwellis Showcases Aquadex System at Critical Care Cardiology Summit
- Clinical Utility Highlight: At the 4th Annual Critical Care Cardiology Education Summit hosted by the University of Minnesota, Nuwellis showcased the clinical utility of its Aquadex SmartFlow® system, with over 280 physicians participating in training, marking a significant promotional effort for the technology in cardiac critical care.
- Hands-On Training Opportunity: The conference provided participants with practical training on Aquadex technology, equipping physicians with essential fluid management skills for complex patients, thereby enhancing their professional capabilities in cardiac intensive care.
- Educational Advocacy: Nuwellis CEO John Erb noted that the summit offered a valuable opportunity to introduce Aquadex to numerous cardiology fellows and practicing physicians, emphasizing the critical role of precise fluid management in caring for critically ill patients.
- Industry Impact: The summit focused on managing bleeding and coagulopathy in critically ill cardiac patients, and through participation in such educational initiatives, Nuwellis further solidified its influence in the cardiac critical care field, promoting the adoption of innovative fluid management strategies.
See More
Nuwellis Appoints New CEO, Stock Drops
- New CEO Appointment: Nuwellis announced the appointment of Mike McCormick as CEO effective June 30, 2026, succeeding current chairman John Erb, indicating a significant leadership change within the company.
- Extensive Leadership Experience: McCormick brings over three decades of healthcare technology leadership experience and served on Nuwellis' board from 2023 to 2026, providing a strong industry background for his upcoming role.
- Negative Stock Reaction: Following the announcement, Nuwellis' shares fell by 4.76%, reflecting market concerns regarding this leadership transition, which may impact investor confidence.
- Uncertain Future Outlook: While McCormick's appointment could bring new strategic directions, the market remains cautious about Nuwellis' future performance, particularly in the context of intense competition in the healthcare technology sector.
See More
Nuwellis Appoints New CEO to Drive Growth
- New CEO Appointment: Nuwellis has announced the appointment of Mike McCormick as CEO effective June 30, 2026, succeeding current CEO John Erb, who will remain as Chairman of the Board to ensure a smooth leadership transition.
- Extensive Leadership Experience: McCormick brings over 30 years of leadership experience in the medical technology sector, having founded and led companies across various healthcare markets, which positions him well to drive Nuwellis's next phase of growth through strong commercialization and strategic execution.
- Market Opportunity Expansion: McCormick emphasized the opportunity for Nuwellis to expand its role in precision fluid management, planning to collaborate with employees, leadership, and clinicians to enhance commercial execution and advance the product pipeline, thereby creating value for patients and shareholders.
- Strategic Vision: The appointment of the new CEO marks a strategic transformation for Nuwellis in the medical technology field, aiming to improve patient care quality through innovative solutions and strengthen the company's market position in managing complex cardiorenal conditions.
See More
Nuwellis Expands Collaboration with South Carolina Healthcare System
- Collaboration Expansion: Nuwellis has expanded its collaboration with a major South Carolina healthcare system to integrate Aquadex SmartFlow® devices into clinical care programs at a children's hospital, which is expected to benefit more pediatric patients in need of treatment.
- Device Upgrade: The healthcare system has upgraded to the latest Aquadex devices at its two existing locations, assisting clinicians in providing controlled and predictable fluid removal for pediatric patients suffering from fluid overload, thereby enhancing treatment outcomes.
- FDA Submission Plans: Nuwellis recently completed a pre-submission meeting with the U.S. Food and Drug Administration (FDA) and plans to submit an application by the end of 2026 to expand the Aquadex SmartFlow® System's label to support pediatric patients weighing 5 kg and above.
- Market Leadership: Nuwellis CEO John Erb stated that this collaboration further validates the clinical importance of its ultrafiltration system while reinforcing the company's leadership and continued momentum in the pediatric category.
See More
Nuwellis Celebrates Five-Year Support for PC4 Conference
- Support for Pediatric Care: Nuwellis has consistently supported the Pediatric Cardiac Critical Care Consortium (PC4) annual conference over the past five years, aiming to enhance the quality of care for critically ill children with cardiovascular diseases, reflecting the company's strong commitment to improving pediatric care.
- Education and Exchange: By collaborating with leading pediatric cardiac critical care institutions, Nuwellis has fostered clinician education and scientific exchange on fluid management strategies, helping to raise awareness of the importance of fluid balance and improving care outcomes for critically ill patients.
- Device Utilization Promotion: Many top pediatric cardiac centers participating in PC4 utilize the Aquadex® SmartFlow® system to manage fluid overload in complex pediatric patients, with Nuwellis supporting multidisciplinary care teams through ongoing education and training to ensure effective device use and patient safety.
- Market Strategic Focus: Nuwellis views the pediatric market as a critical strategic focus, continuing to strengthen relationships with leading pediatric centers and physician leaders while supporting forums and collaborative initiatives to facilitate the exchange of best practices in fluid management.
See More
Nuwellis CEO Outlines Strategic Priorities for 2026
- Leadership Transition: Nuwellis announced that Mike McCormick will assume the role of CEO on June 30, 2026, while former CEO John Erb will remain as Chairman, aiming to leverage the company's growing commercial momentum and improved margins.
- Strong Financial Performance: In Q1 2026, Nuwellis achieved a 26% year-over-year revenue growth with a gross margin of 70.1%, a 14-point improvement from the previous year, reflecting the continued adoption of its technology and employee dedication.
- Strategic Acquisition: Nuwellis acquired Rendiatech, Inc., enhancing its market position in the ICU by adding automated kidney function monitoring technology to its portfolio, creating additional growth opportunities within its existing customer base.
- Optimized Capital Management: The company strengthened its capital position to execute key commercial and development initiatives while maintaining its Nasdaq listing, focusing on disciplined capital allocation to drive long-term shareholder value.
See More
Nuwellis Showcases Aquadex System at Critical Care Cardiology Summit
- Clinical Utility Highlight: At the 4th Annual Critical Care Cardiology Education Summit hosted by the University of Minnesota, Nuwellis showcased the clinical utility of its Aquadex SmartFlow® system, with over 280 physicians participating in training, marking a significant promotional effort for the technology in cardiac critical care.
- Hands-On Training Opportunity: The conference provided participants with practical training on Aquadex technology, equipping physicians with essential fluid management skills for complex patients, thereby enhancing their professional capabilities in cardiac intensive care.
- Educational Advocacy: Nuwellis CEO John Erb noted that the summit offered a valuable opportunity to introduce Aquadex to numerous cardiology fellows and practicing physicians, emphasizing the critical role of precise fluid management in caring for critically ill patients.
- Industry Impact: The summit focused on managing bleeding and coagulopathy in critically ill cardiac patients, and through participation in such educational initiatives, Nuwellis further solidified its influence in the cardiac critical care field, promoting the adoption of innovative fluid management strategies.
See More
Nuwellis Appoints New CEO, Stock Drops
- New CEO Appointment: Nuwellis announced the appointment of Mike McCormick as CEO effective June 30, 2026, succeeding current chairman John Erb, indicating a significant leadership change within the company.
- Extensive Leadership Experience: McCormick brings over three decades of healthcare technology leadership experience and served on Nuwellis' board from 2023 to 2026, providing a strong industry background for his upcoming role.
- Negative Stock Reaction: Following the announcement, Nuwellis' shares fell by 4.76%, reflecting market concerns regarding this leadership transition, which may impact investor confidence.
- Uncertain Future Outlook: While McCormick's appointment could bring new strategic directions, the market remains cautious about Nuwellis' future performance, particularly in the context of intense competition in the healthcare technology sector.
See More
Nuwellis Appoints New CEO to Drive Growth
- New CEO Appointment: Nuwellis has announced the appointment of Mike McCormick as CEO effective June 30, 2026, succeeding current CEO John Erb, who will remain as Chairman of the Board to ensure a smooth leadership transition.
- Extensive Leadership Experience: McCormick brings over 30 years of leadership experience in the medical technology sector, having founded and led companies across various healthcare markets, which positions him well to drive Nuwellis's next phase of growth through strong commercialization and strategic execution.
- Market Opportunity Expansion: McCormick emphasized the opportunity for Nuwellis to expand its role in precision fluid management, planning to collaborate with employees, leadership, and clinicians to enhance commercial execution and advance the product pipeline, thereby creating value for patients and shareholders.
- Strategic Vision: The appointment of the new CEO marks a strategic transformation for Nuwellis in the medical technology field, aiming to improve patient care quality through innovative solutions and strengthen the company's market position in managing complex cardiorenal conditions.
See More
Nuwellis Expands Collaboration with South Carolina Healthcare System
- Collaboration Expansion: Nuwellis has expanded its collaboration with a major South Carolina healthcare system to integrate Aquadex SmartFlow® devices into clinical care programs at a children's hospital, which is expected to benefit more pediatric patients in need of treatment.
- Device Upgrade: The healthcare system has upgraded to the latest Aquadex devices at its two existing locations, assisting clinicians in providing controlled and predictable fluid removal for pediatric patients suffering from fluid overload, thereby enhancing treatment outcomes.
- FDA Submission Plans: Nuwellis recently completed a pre-submission meeting with the U.S. Food and Drug Administration (FDA) and plans to submit an application by the end of 2026 to expand the Aquadex SmartFlow® System's label to support pediatric patients weighing 5 kg and above.
- Market Leadership: Nuwellis CEO John Erb stated that this collaboration further validates the clinical importance of its ultrafiltration system while reinforcing the company's leadership and continued momentum in the pediatric category.
See More
